The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer

Immune checkpoint blockade (ICB) has become a standard treatment for non-small cell lung cancer (NSCLC). However, most patients with NSCLC do not benefit from these treatments. Abnormal vasculature is a hallmark of solid tumors and is involved in tumor immune escape. These abnormalities stem from th...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Sijia, Xiong, Xinxin, You, Hua, Shen, Jianfei, Zhou, Penghui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206805/
https://www.ncbi.nlm.nih.gov/pubmed/34149730
http://dx.doi.org/10.3389/fimmu.2021.689132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206805/
https://www.ncbi.nlm.nih.gov/pubmed/34149730
http://dx.doi.org/10.3389/fimmu.2021.689132

Ejemplares similares